SLN
OTC MARKETS · Biotechnology

Silence Therapeutics PLC

Small-Cap Stocks Biotech Stocks Healthcare Stocks
$19.80
+0.03 (+0.15%)
SLN News1 articles
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.
Markets